Viral Vector Manufacturing for Gene Therapy refers to the specialized process of producing viral vectors, which are engineered viruses used to deliver therapeutic genetic material into patients' cells. This process involves several stages, including design, production, purification, and quality control, to ensure that the viral vectors are safe, effective, and compliant with regulatory standards.
Viral vector manufacturing is crucial for the development and delivery of gene therapies, which aim to treat genetic disorders, cancers, and other diseases by introducing, removing, or altering genetic material within a patient’s cells. The manufacturing process ensures that these therapies are safe, effective, and ready for clinical use.
The global Viral Vector Manufacturing for Gene Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of %during the forecast period.
The US & Canada market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The China market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The Europe market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key manufacturers of Viral Vector Manufacturing for Gene Therapy include Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Viral Vector Manufacturing for Gene Therapy market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Viral Vector Manufacturing for Gene Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Viral Vector Manufacturing for Gene Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Viral Vector Manufacturing for Gene Therapy revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Viral Vector Manufacturing for Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Viral Vector Manufacturing for Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), etc.
Market Segmentation
By Company
Thermo Fisher Scientific
Lonza
Catalent
Charles River
Merck
SK pharmteco
Oxford Biomedica
AGC Biologics（MolMed）
Gene Universal
Polyplus (Sartorius)
CCRM
FUJIFILM Diosynth Biotechnologies
Biovian
Miltenyi Bioindustry
Aldevron
Takara Bio
Yposkesi
Genezen
Exthera
Flash Therapeutics
VIVEBiotech
FinVector
Eurogentec
VGXI
GenScript ProBio
EurekaBio
Obio Technology
GeneSail Biotech
VectorBuilder
WuXi ATU
Ubrigene
Porton Biologics
Pharmaron
PackGene Biotechnology
Hillgene
Asymchem
Segment by Type
AAV
Lentivirus
Adenovirus
HSV
Others
Segment by Application
Vaccine Development
Gene Therapy
Academic Scientific Research Institution
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of South America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Viral Vector Manufacturing for Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vector Manufacturing for Gene Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector Manufacturing for Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Viral Vector Manufacturing for Gene Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030 1.2.2 AAV 1.2.3 Lentivirus 1.2.4 Adenovirus 1.2.5 HSV 1.2.6 Others 1.3 Market by Application 1.3.1 Global Viral Vector Manufacturing for Gene Therapy Market Share by Application: 2019 VS 2023 VS 2030 1.3.2 Vaccine Development 1.3.3 Gene Therapy 1.3.4 Academic Scientific Research Institution 1.3.5 Others 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Global Growth Trends 2.1 Global Viral Vector Manufacturing for Gene Therapy Market Perspective (2019-2030) 2.2 Global Viral Vector Manufacturing for Gene Therapy Growth Trends by Region 2.2.1 Global Viral Vector Manufacturing for Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030 2.2.2 Viral Vector Manufacturing for Gene Therapy Historic Market Size by Region (2019-2024) 2.2.3 Viral Vector Manufacturing for Gene Therapy Forecasted Market Size by Region (2025-2030) 2.3 Viral Vector Manufacturing for Gene Therapy Market Dynamics 2.3.1 Viral Vector Manufacturing for Gene Therapy Industry Trends 2.3.2 Viral Vector Manufacturing for Gene Therapy Market Drivers 2.3.3 Viral Vector Manufacturing for Gene Therapy Market Challenges 2.3.4 Viral Vector Manufacturing for Gene Therapy Market Restraints 3 Competition Landscape by Key Players 3.1 Global Revenue Viral Vector Manufacturing for Gene Therapy by Players 3.1.1 Global Viral Vector Manufacturing for Gene Therapy Revenue by Players (2019-2024) 3.1.2 Global Viral Vector Manufacturing for Gene Therapy Revenue Market Share by Players (2019-2024) 3.2 Global Viral Vector Manufacturing for Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Global Key Players of Viral Vector Manufacturing for Gene Therapy, Ranking by Revenue, 2022 VS 2023 VS 2024 3.4 Global Viral Vector Manufacturing for Gene Therapy Market Concentration Ratio 3.4.1 Global Viral Vector Manufacturing for Gene Therapy Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Viral Vector Manufacturing for Gene Therapy Revenue in 2023 3.5 Global Key Players of Viral Vector Manufacturing for Gene Therapy Head office and Area Served 3.6 Global Key Players of Viral Vector Manufacturing for Gene Therapy, Product and Application 3.7 Global Key Players of Viral Vector Manufacturing for Gene Therapy, Date of Enter into This Industry 3.8 Mergers & Acquisitions, Expansion Plans 4 Viral Vector Manufacturing for Gene Therapy Breakdown Data by Type 4.1 Global Viral Vector Manufacturing for Gene Therapy Historic Market Size by Type (2019-2024) 4.2 Global Viral Vector Manufacturing for Gene Therapy Forecasted Market Size by Type (2025-2030) 5 Viral Vector Manufacturing for Gene Therapy Breakdown Data by Application 5.1 Global Viral Vector Manufacturing for Gene Therapy Historic Market Size by Application (2019-2024) 5.2 Global Viral Vector Manufacturing for Gene Therapy Forecasted Market Size by Application (2025-2030) 6 North America 6.1 North America Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030) 6.2 North America Viral Vector Manufacturing for Gene Therapy Market Size by Type 6.2.1 North America Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024) 6.2.2 North America Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030) 6.2.3 North America Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030) 6.3 North America Viral Vector Manufacturing for Gene Therapy Market Size by Application 6.3.1 North America Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024) 6.3.2 North America Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030) 6.3.3 North America Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030) 6.4 North America Viral Vector Manufacturing for Gene Therapy Market Size by Country 6.4.1 North America Viral Vector Manufacturing for Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030 6.4.2 North America Viral Vector Manufacturing for Gene Therapy Market Size by Country (2019-2024) 6.4.3 North America Viral Vector Manufacturing for Gene Therapy Market Share by Country (2025-2030) 6.4.4 United States 6.4.5 Canada 7 Europe 7.1 Europe Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030) 7.2 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Type 7.2.1 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024) 7.2.2 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030) 7.2.3 Europe Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030) 7.3 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Application 7.3.1 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024) 7.3.2 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030) 7.3.3 Europe Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030) 7.4 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Country 7.4.1 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030 7.4.2 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Country (2019-2024) 7.4.3 Europe Viral Vector Manufacturing for Gene Therapy Market Size by Country (2025-2030) 7.4.4 Germany 7.4.5 France 7.4.6 U.K. 7.4.7 Italy 7.4.8 Russia 7.4.9 Nordic Countries 8 China 8.1 China Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030) 8.2 China Viral Vector Manufacturing for Gene Therapy Market Size by Type 8.2.1 China Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024) 8.2.2 China Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030) 8.2.3 China Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030) 8.3 China Viral Vector Manufacturing for Gene Therapy Market Size by Application 8.3.1 China Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024) 8.3.2 China Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030) 8.3.3 China Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030) 9 Asia (excluding China) 9.1 Asia Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030) 9.2 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Type 9.2.1 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024) 9.2.2 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030) 9.2.3 Asia Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030) 9.3 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Application 9.3.1 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024) 9.3.2 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030) 9.3.3 Asia Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030) 9.4 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Region 9.4.1 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030 9.4.2 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Region (2019-2024) 9.4.3 Asia Viral Vector Manufacturing for Gene Therapy Market Size by Region (2025-2030) 9.4.4 Japan 9.4.5 South Korea 9.4.6 China Taiwan 9.4.7 Southeast Asia 9.4.8 India 9.4.9 Australia 10 Middle East, Africa, and Latin America 10.1 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size (2019-2030) 10.2 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Type 10.2.1 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Type (2019-2024) 10.2.2 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Type (2025-2030) 10.2.3 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Share by Type (2019-2030) 10.3 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Application 10.3.1 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Application (2019-2024) 10.3.2 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Application (2025-2030) 10.3.3 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Share by Application (2019-2030) 10.4 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Country 10.4.1 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030 10.4.2 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Country (2019-2024) 10.4.3 Middle East, Africa, and Latin America Viral Vector Manufacturing for Gene Therapy Market Size by Country (2025-2030) 10.4.4 Brazil 10.4.5 Mexico 10.4.6 Turkey 10.4.7 Saudi Arabia 10.4.8 Israel 10.4.9 GCC Countries 11 Key Players Profiles 11.1 Thermo Fisher Scientific 11.1.1 Thermo Fisher Scientific Company Details 11.1.2 Thermo Fisher Scientific Business Overview 11.1.3 Thermo Fisher Scientific Viral Vector Manufacturing for Gene Therapy Introduction 11.1.4 Thermo Fisher Scientific Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.1.5 Thermo Fisher Scientific Recent Development 11.2 Lonza 11.2.1 Lonza Company Details 11.2.2 Lonza Business Overview 11.2.3 Lonza Viral Vector Manufacturing for Gene Therapy Introduction 11.2.4 Lonza Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.2.5 Lonza Recent Development 11.3 Catalent 11.3.1 Catalent Company Details 11.3.2 Catalent Business Overview 11.3.3 Catalent Viral Vector Manufacturing for Gene Therapy Introduction 11.3.4 Catalent Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.3.5 Catalent Recent Development 11.4 Charles River 11.4.1 Charles River Company Details 11.4.2 Charles River Business Overview 11.4.3 Charles River Viral Vector Manufacturing for Gene Therapy Introduction 11.4.4 Charles River Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.4.5 Charles River Recent Development 11.5 Merck 11.5.1 Merck Company Details 11.5.2 Merck Business Overview 11.5.3 Merck Viral Vector Manufacturing for Gene Therapy Introduction 11.5.4 Merck Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.5.5 Merck Recent Development 11.6 SK pharmteco 11.6.1 SK pharmteco Company Details 11.6.2 SK pharmteco Business Overview 11.6.3 SK pharmteco Viral Vector Manufacturing for Gene Therapy Introduction 11.6.4 SK pharmteco Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.6.5 SK pharmteco Recent Development 11.7 Oxford Biomedica 11.7.1 Oxford Biomedica Company Details 11.7.2 Oxford Biomedica Business Overview 11.7.3 Oxford Biomedica Viral Vector Manufacturing for Gene Therapy Introduction 11.7.4 Oxford Biomedica Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.7.5 Oxford Biomedica Recent Development 11.8 AGC Biologics（MolMed） 11.8.1 AGC Biologics（MolMed） Company Details 11.8.2 AGC Biologics（MolMed） Business Overview 11.8.3 AGC Biologics（MolMed） Viral Vector Manufacturing for Gene Therapy Introduction 11.8.4 AGC Biologics（MolMed） Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.8.5 AGC Biologics（MolMed） Recent Development 11.9 Gene Universal 11.9.1 Gene Universal Company Details 11.9.2 Gene Universal Business Overview 11.9.3 Gene Universal Viral Vector Manufacturing for Gene Therapy Introduction 11.9.4 Gene Universal Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.9.5 Gene Universal Recent Development 11.10 Polyplus (Sartorius) 11.10.1 Polyplus (Sartorius) Company Details 11.10.2 Polyplus (Sartorius) Business Overview 11.10.3 Polyplus (Sartorius) Viral Vector Manufacturing for Gene Therapy Introduction 11.10.4 Polyplus (Sartorius) Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.10.5 Polyplus (Sartorius) Recent Development 11.11 CCRM 11.11.1 CCRM Company Details 11.11.2 CCRM Business Overview 11.11.3 CCRM Viral Vector Manufacturing for Gene Therapy Introduction 11.11.4 CCRM Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.11.5 CCRM Recent Development 11.12 FUJIFILM Diosynth Biotechnologies 11.12.1 FUJIFILM Diosynth Biotechnologies Company Details 11.12.2 FUJIFILM Diosynth Biotechnologies Business Overview 11.12.3 FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing for Gene Therapy Introduction 11.12.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.12.5 FUJIFILM Diosynth Biotechnologies Recent Development 11.13 Biovian 11.13.1 Biovian Company Details 11.13.2 Biovian Business Overview 11.13.3 Biovian Viral Vector Manufacturing for Gene Therapy Introduction 11.13.4 Biovian Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.13.5 Biovian Recent Development 11.14 Miltenyi Bioindustry 11.14.1 Miltenyi Bioindustry Company Details 11.14.2 Miltenyi Bioindustry Business Overview 11.14.3 Miltenyi Bioindustry Viral Vector Manufacturing for Gene Therapy Introduction 11.14.4 Miltenyi Bioindustry Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.14.5 Miltenyi Bioindustry Recent Development 11.15 Aldevron 11.15.1 Aldevron Company Details 11.15.2 Aldevron Business Overview 11.15.3 Aldevron Viral Vector Manufacturing for Gene Therapy Introduction 11.15.4 Aldevron Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.15.5 Aldevron Recent Development 11.16 Takara Bio 11.16.1 Takara Bio Company Details 11.16.2 Takara Bio Business Overview 11.16.3 Takara Bio Viral Vector Manufacturing for Gene Therapy Introduction 11.16.4 Takara Bio Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.16.5 Takara Bio Recent Development 11.17 Yposkesi 11.17.1 Yposkesi Company Details 11.17.2 Yposkesi Business Overview 11.17.3 Yposkesi Viral Vector Manufacturing for Gene Therapy Introduction 11.17.4 Yposkesi Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.17.5 Yposkesi Recent Development 11.18 Genezen 11.18.1 Genezen Company Details 11.18.2 Genezen Business Overview 11.18.3 Genezen Viral Vector Manufacturing for Gene Therapy Introduction 11.18.4 Genezen Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.18.5 Genezen Recent Development 11.19 Exthera 11.19.1 Exthera Company Details 11.19.2 Exthera Business Overview 11.19.3 Exthera Viral Vector Manufacturing for Gene Therapy Introduction 11.19.4 Exthera Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.19.5 Exthera Recent Development 11.20 Flash Therapeutics 11.20.1 Flash Therapeutics Company Details 11.20.2 Flash Therapeutics Business Overview 11.20.3 Flash Therapeutics Viral Vector Manufacturing for Gene Therapy Introduction 11.20.4 Flash Therapeutics Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.20.5 Flash Therapeutics Recent Development 11.21 VIVEBiotech 11.21.1 VIVEBiotech Company Details 11.21.2 VIVEBiotech Business Overview 11.21.3 VIVEBiotech Viral Vector Manufacturing for Gene Therapy Introduction 11.21.4 VIVEBiotech Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.21.5 VIVEBiotech Recent Development 11.22 FinVector 11.22.1 FinVector Company Details 11.22.2 FinVector Business Overview 11.22.3 FinVector Viral Vector Manufacturing for Gene Therapy Introduction 11.22.4 FinVector Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.22.5 FinVector Recent Development 11.23 Eurogentec 11.23.1 Eurogentec Company Details 11.23.2 Eurogentec Business Overview 11.23.3 Eurogentec Viral Vector Manufacturing for Gene Therapy Introduction 11.23.4 Eurogentec Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.23.5 Eurogentec Recent Development 11.24 VGXI 11.24.1 VGXI Company Details 11.24.2 VGXI Business Overview 11.24.3 VGXI Viral Vector Manufacturing for Gene Therapy Introduction 11.24.4 VGXI Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.24.5 VGXI Recent Development 11.25 GenScript ProBio 11.25.1 GenScript ProBio Company Details 11.25.2 GenScript ProBio Business Overview 11.25.3 GenScript ProBio Viral Vector Manufacturing for Gene Therapy Introduction 11.25.4 GenScript ProBio Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.25.5 GenScript ProBio Recent Development 11.26 EurekaBio 11.26.1 EurekaBio Company Details 11.26.2 EurekaBio Business Overview 11.26.3 EurekaBio Viral Vector Manufacturing for Gene Therapy Introduction 11.26.4 EurekaBio Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.26.5 EurekaBio Recent Development 11.27 Obio Technology 11.27.1 Obio Technology Company Details 11.27.2 Obio Technology Business Overview 11.27.3 Obio Technology Viral Vector Manufacturing for Gene Therapy Introduction 11.27.4 Obio Technology Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.27.5 Obio Technology Recent Development 11.28 GeneSail Biotech 11.28.1 GeneSail Biotech Company Details 11.28.2 GeneSail Biotech Business Overview 11.28.3 GeneSail Biotech Viral Vector Manufacturing for Gene Therapy Introduction 11.28.4 GeneSail Biotech Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.28.5 GeneSail Biotech Recent Development 11.29 VectorBuilder 11.29.1 VectorBuilder Company Details 11.29.2 VectorBuilder Business Overview 11.29.3 VectorBuilder Viral Vector Manufacturing for Gene Therapy Introduction 11.29.4 VectorBuilder Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.29.5 VectorBuilder Recent Development 11.30 WuXi ATU 11.30.1 WuXi ATU Company Details 11.30.2 WuXi ATU Business Overview 11.30.3 WuXi ATU Viral Vector Manufacturing for Gene Therapy Introduction 11.30.4 WuXi ATU Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.30.5 WuXi ATU Recent Development 11.31 Ubrigene 11.31.1 Ubrigene Company Details 11.31.2 Ubrigene Business Overview 11.31.3 Ubrigene Viral Vector Manufacturing for Gene Therapy Introduction 11.31.4 Ubrigene Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.31.5 Ubrigene Recent Development 11.32 Porton Biologics 11.32.1 Porton Biologics Company Details 11.32.2 Porton Biologics Business Overview 11.32.3 Porton Biologics Viral Vector Manufacturing for Gene Therapy Introduction 11.32.4 Porton Biologics Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.32.5 Porton Biologics Recent Development 11.33 Pharmaron 11.33.1 Pharmaron Company Details 11.33.2 Pharmaron Business Overview 11.33.3 Pharmaron Viral Vector Manufacturing for Gene Therapy Introduction 11.33.4 Pharmaron Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.33.5 Pharmaron Recent Development 11.34 PackGene Biotechnology 11.34.1 PackGene Biotechnology Company Details 11.34.2 PackGene Biotechnology Business Overview 11.34.3 PackGene Biotechnology Viral Vector Manufacturing for Gene Therapy Introduction 11.34.4 PackGene Biotechnology Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.34.5 PackGene Biotechnology Recent Development 11.35 Hillgene 11.35.1 Hillgene Company Details 11.35.2 Hillgene Business Overview 11.35.3 Hillgene Viral Vector Manufacturing for Gene Therapy Introduction 11.35.4 Hillgene Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.35.5 Hillgene Recent Development 11.36 Asymchem 11.36.1 Asymchem Company Details 11.36.2 Asymchem Business Overview 11.36.3 Asymchem Viral Vector Manufacturing for Gene Therapy Introduction 11.36.4 Asymchem Revenue in Viral Vector Manufacturing for Gene Therapy Business (2019-2024) 11.36.5 Asymchem Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.1.1 Research Programs/Design 13.1.1.2 Market Size Estimation 13.1.1.3 Market Breakdown and Data Triangulation 13.1.2 Data Source 13.1.2.1 Secondary Sources 13.1.2.2 Primary Sources 13.2 Author Details 13.3 Disclaimer